Breaking News Instant updates and real-time market news.

AAPL

Apple

$195.07

6.93 (3.68%)

, AMD

AMD

$27.90

2.2 (8.56%)

07:35
03/22/19
03/22
07:35
03/22/19
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Thursday in Apple (AAPL), Advanced Micro (AMD), Square (SQ), Kroger (KR), Marvell (MRVL), Extended Stay America (STAY), Ionis Pharmaceuticals (IONS), Pilgrims Pride (PPC), Sleep Number (SNBR), and Xperi Corp (XPER).

AAPL

Apple

$195.07

6.93 (3.68%)

AMD

AMD

$27.90

2.2 (8.56%)

SQ

Square

$78.58

3.36 (4.47%)

KR

Kroger

$24.33

0.35 (1.46%)

MRVL

Marvell

$20.80

0.79 (3.95%)

STAY

Extended Stay America

$18.39

0.4 (2.22%)

IONS

Ionis Pharmaceuticals

$80.53

0.25 (0.31%)

PPC

Pilgrim's Pride

$21.32

0.71 (3.44%)

SNBR

Sleep Number

$47.83

1.07 (2.29%)

XPER

Xperi

$24.29

0.38 (1.59%)

  • 22

    Mar

  • 25

    Mar

  • 25

    Mar

  • 27

    Mar

  • 28

    Mar

  • 01

    Apr

  • 01

    May

  • 28

    May

  • 30

    May

AAPL Apple
$195.07

6.93 (3.68%)

03/21/19
WEDB
03/21/19
NO CHANGE
Target $215
WEDB
Outperform
Apple price target raised to $215 from $200 at Wedbush
Wedbush analyst Daniel Ives raised his price target for Apple (AAPL) to $215 from $200 ahead of the expected announcement of its "long awaited" streaming video service that will compete with the likes of Netflix (NFLX), Disney (DIS), Hulu, among others. The analyst views this as a pivotal step in further driving Apple's services flywheel, and believes it will only be the drumroll to a more transformative content acquisition during the course of 2019 for Apple. The services business remains the "wild card" in driving the valuation higher for Apple as he estimates the valuation of the services franchise for the company is worth roughly $400B on a standalone basis with this highly profitable segment poised to exceed $50B in revenues by 2020. Ives reiterates an Outperform rating on Apple's shares.
03/21/19
03/21/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) upgraded to Strong Buy from Buy at Needham with analyst Laura Martin stating that Apple has five types of "network effects," including the strongest type, namely hardware-based direct network effects. 2. Qorvo (QRVO) upgraded to Buy from Neutral at Goldman Sachs with analyst Toshiya Hari saying he's beginning to see early signs of smartphone unit stabilization with channel checks indicating near-term upside in China will offset "marginal weakness" at Apple. 3. Arista Networks (ANET) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Rod Hall seeing "significant upside potential" to consensus expectations driven by Arista's expansion into campus switching. 4. ConocoPhillips (COP) upgraded to Overweight from Neutral at Piper Jaffray with analyst Blake Fernandez attributing the stock's year-to-date underperformance to concern over major project spending risk, which he believes is embedded in current valuation levels. 5. Diplomat Pharmacy (DPLO) upgraded to Outperform from Market Perform at Raymond James with analyst John Ransom saying the 56% decline in shares since the February earnings delay provides a valuation that could be attractive to a strategic buyer. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/21/19
RHCO
03/21/19
NO CHANGE
RHCO
Apple event may be negative for Netflix, positive for Lions Gate, says SunTrust
SunTrust analyst Matthew Thornton previews Apple's (AAPL) media event scheduled for March 25th, saying the company is likely to unveil a Video Service. The analyst believes that an Apple OTT service could be a positive for Lions Gate (LGF.B) given the participation of the Starz networks but negative for Netflix (NFLX) "if Apple can offer compelling content bundles at compelling prices with a compelling UI and ubiquitous access". Thornton adds that Apple's bundling of its Music with video subscriptions and news subscriptions may be a negative for Spotify (SPOT) and a "modest incremental negative" for Roku (ROKU) if Apple's service app is not on its service.
03/22/19
JPMS
03/22/19
UPGRADE
Target $65
JPMS
Overweight
JPMorgan upgrades Lumentum to Overweight on iPhone volume stabilization
JPMorgan analyst Samik Chatterjee upgraded Lumentum Holdings (LITE) to Overweight from Neutral and raised his price target for the shares to $65 from $50. The stock closed yesterday up $2.44, of 5%, to $52.10. The analyst sees a "solid" outlook for the company's telecom business amid "strong" growth led by 5G investments and upside to synergy targets relative to recent acquisition of Oclaro. Further, he sees limited downside risk relative to volume expectations for Apple's (AAPL) iPhone, which he notes has been a "key driver of sentiment on the shares." Stabilization of its iPhone volume outlook should drive focus back to the "strong" fundamentals in Lumentum's primary telecom business, Chatterjee tells investors in a research note.
AMD AMD
$27.90

2.2 (8.56%)

03/20/19
JEFF
03/20/19
NO CHANGE
Target $26
JEFF
Buy
AMD CEO attending Google event suggests close partnership, says Jefferies
Google's (GOOG, GOOGL) announcement yesterday that it was using a custom AMD (AMD) graphics processing units for its cloud-based gaming platform Stadia is likely to lead to an announcement that Google will use AMD EPYC server microprocessors as well, Jefferies analyst Mark Lipacis tells investors in a research note. AMD CEO's attendance at the Google event suggests a close partnership, says the analyst. His sense is that consensus believes AMD would be lucky to get 10% of the server market over the next 12-24 months. However, Lipacis views this "bogey as conservative." He keeps a Buy rating on AMD with a $26 price target.
02/15/19
RSBL
02/15/19
NO CHANGE
Target $190
RSBL
Buy
Nvidia price target raised to $190 from $170 at Rosenblatt
Rosenblatt analyst Hans Mosesmann raised his price target for Nvidia (NVDA) to $190 and reiterates a Buy rating on the shares following the company's Q4 results. The "crypto mess" is finally bottoming in the April quarter and management sees a "material snap-back" starting in fiscal Q2 and the rest of the year, Mosesmann tells investors in a post-earnings research note titled "Crypto Bottoming - Aggressive Snapback - Stock Works for LT Investors." However, amid Datacenter and Gaming industry uncertainty, the analyst believes management is "needlessly being aggressive" with its outlook. He points out that, though, that both Intel (INTC) and AMD (AMD) are also being aggressive for their own year guides. Mosesmann remains a long-term bull on the Nvidia story and believes new traction in inferencing and enterprise market segments will sustain high growth rates in Datacenter for years to come.
03/20/19
OPCO
03/20/19
NO CHANGE
Target $26
OPCO
Perform
AMD gets 'positive win' with Google cloud gaming, says Oppenheimer
Google (GOOGL, GOOG) yesterday formally announced entry into cloud-based gaming with the Stadia platform and confirmed it will use custom AMD (AMD) graphics processing units, Oppenheimer analyst Rick Schafer tells investors in a research note. However, the announcement wasn't entirely new as AMD CEO Lisa Su highlighted earlier this year that the company's Radeon GPUs were used in Google's Project Stream beta test, the analyst adds. Nonetheless, Schafer sees the confirmation from Google as "validation and a positive win" for AMD. His estimates for the company are unchanged pending a better sense of how incremental the win is to the model. The analyst keeps a Perform rating on AMD with a $26 price target. Competition is heating up in cloud-based gaming with Nvidia (NVDA) this week announcing the GeForce NOW Alliance with initial partners SoftBank and LG, Schafer writes. He believes cloud gaming is likely to cannibalize the casual console and mobile gamer over time. While a shift to cloud gaming is likely a net positive for AMD, the company's dominant position in console today could represent a drag, the analyst contends.
02/13/19
RBCM
02/13/19
NO CHANGE
RBCM
RBC Capital sees Google data centers news as positive for AMD, Nvidia
RBC Capital analyst Mitch Steves sees news of Google (GOOG; GOOGL) planning to spend about $13B to build new data centers in Nevada, Ohio, Texas and Nebraska along with additional expansion plans for the Virginia and NY City campuses as an incremental positive for AMD (AMD), Nvidia (NVDA), Arista Networks (ANET) and the Semi-cap equipment group, including Lam Research (LRCX), ASML (ASML), and Applied Materials (AMAT). One of the material concerns over the past few months has been hyperscale spending and this announcement should help quell fears surrounding a weaker spending environment, he contends.
SQ Square
$78.58

3.36 (4.47%)

02/28/19
JEFF
02/28/19
NO CHANGE
Target $73
JEFF
Hold
Square price target raised to $73 from $64 at Jefferies
Jefferies analyst John Hecht raised his price target for Square to $73 saying the company reported "strong" Q4 results. The analyst updated his model to account for guidance and recent trends. He keeps a Hold rating on the shares.
02/28/19
KEYB
02/28/19
NO CHANGE
Target $100
KEYB
Overweight
Square price target lowered to $100 from $115 at KeyBanc
KeyBanc analyst Josh Beck lowered his price target for Square to $100 from $115 on lower EBITDA estimates, yet strong unit economics. The analyst notes that Square beat Q4 buoyed by subscription/services growth, and with Square Cash MAUs doubling to 15M. The pace of innovation remains "impressive," including the launch of Square Card, and the addition of benefits to payroll, he contends. Beck reiterates an Overweight rating on the shares.
03/05/19
NOMU
03/05/19
NO CHANGE
Target $105
NOMU
Buy
Downloads of Square's Cash App accelerating, says Nomura Instinet
Nomura Instinet analyst Dan Dolev lowered his price target for Square (SQ) to $105 from $110 while keeping a Buy rating on the shares. The analyst's Cash App versus PayPal's (PYPL) Venmo payments app tracker points to a "healthy pace" of downloads in February with 2.1M additional downloads, and year-over-year download growth accelerating for the second consecutive month to 37%. With 15M active users in December, the number of active Cash App users has more than doubled year-over-year, resulting in a slight improvement to the ratio of active versus total downloads, Dolev tells investors in a research note.
03/19/19
SBSH
03/19/19
NO CHANGE
SBSH
Global Payments and TSYS rise on Citi's preferred Payments list
Citi analyst Ashwin Shirvaikar made changes to his stock rankings in the Payments, Processors & IT Services space following FIS' (FIS) acquisition of Worldpay (WP). Global Payments (GPN) and TSYS (TSS) rise towards the top of the analyst's list. Both are "solid" stand-alone ideas but investors should also discuss whether M&A makes sense for either or both names, Shirvaikar tells investors in a research note. The other change made by the analyst was to swap in Square (SQ) to his highest tranche, or "Elite Eight," instead of FleetCor (FLT).
KR Kroger
$24.33

0.35 (1.46%)

03/21/19
LOOP
03/21/19
NO CHANGE
Target $102
LOOP
Hold
Walmart grocery sales productivity outperforming supermarkets, says Loop Capital
Loop Capital analyst Andrew Wolf kept his Hold rating and $102 price target on Walmart (WMT), saying the company's U.S. grocery comps outperformed the supermarket chains in 2018 as it has since 2016, even though the gap has narrowed. The analyst notes that Kroger (KR) made the biggest strides last year, and that the company was also the best performer in the 2013-2015 period supermarkets last made strong market share gains. Looking ahead, Wolf says the accelerating food-price inflation anticipated by the USDA could also "bode well for continued further same-store sales acceleration for both Walmart and the grocers in 2019."
02/08/19
02/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. American Airlines (AAL) initiated with a Hold at Argus. 2. Walmart (WMT) and Sprouts Farmers Market (SFM) were initiated with a Neutral at Buckingham, while Kroger (KR) was initiated with an Underperform. 3. Wrap Technologies (WRTC) initiated with a Buy at Chardan. 4. nLight (LASR) initiated with a Hold at Craig-Hallum. 5. RA Pharmaceuticals (RARX) initiated with a Buy at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/07/19
BUCK
02/07/19
INITIATION
Target $24
BUCK
Underperform
Kroger initiated with an Underperform at Buckingham
Buckingham analyst Bob Summers started Kroger with an Underperform rating and $24 price target. The company has established an "overly ambitious" goal for fiscal 2020 that entails significant investment, Summers tells investors in a research note. The analyst believes deflation, competitive activity, fuel profitability, and the economic cycle pose risk to the company's EBIT growth.
03/20/19
EVER
03/20/19
INITIATION
Target $27
EVER
In Line
Kroger initiated with an In Line at Evercore ISI
Evercore ISI analyst Michael Montani started Kroger with an In Line rating and $27 base case price target, citing his view that Kroger's efforts to build out its ecosystem are admirable, but it's too soon to expect an "Amazon-esque" flywheel to drive sustainable EBIT growth.
MRVL Marvell
$20.80

0.79 (3.95%)

03/08/19
CHLM
03/08/19
NO CHANGE
Target $19
CHLM
Hold
Marvell shares fully valued at current levels, says Craig-Hallum
Craig-Hallum analyst Christian Schwab maintained a Hold rating and $19 price target on Marvell following the company's Q4 results, telling investors in a research note that FY20 is set to be a challenging year, albeit with an expected bottom in Q1 and improvement through the course of the year. Schwab does believe the company is well positioned with growth prospects in both 5G and automotive, but believes shares remain fully valued at current levels until he sees more tangible traction of the company's growth prospects.
03/08/19
OPCO
03/08/19
NO CHANGE
Target $26
OPCO
Outperform
Oppenheimer says structural bull thesis on Marvell 'intact' after Q4 results
Oppenheimer analyst Rick Schafer reiterated an Outperform rating and $26 price target on Marvell, saying his structural bull thesis is intact following the company's Q4 results. In a research note to investors, Schafer says management noted improvement in bookings over the past few weeks and sees the first quarter as the bottom for Storage and Networking. Shafer says Marvell is undershipping demand, particularly in storage as channel inventories clear. 5G infrastructure is a growth catalyst for late this year and adds that management is executing well through a challenging storage environment made worse by macro uncertainties and ongoing semi cycle correction.
03/01/19
OPCO
03/01/19
NO CHANGE
Target $26
OPCO
Outperform
Oppenheimer says Marvell top 'self-help' story
Oppenheimer analyst Rick Schafer reiterated an Outperform rating and $26 price target on Marvell Technology ahead of the company's March 7 results, which he expects will be in-line to preannounced sales of $740M and a negative bias to the outlook. In a research note to investors, Schafer says storage softness is expected to persist into the April quarter but high-growth networking appears on track, led by early-5G wireless infrastructure builds. Marvell is his top self-help story, and said he remains a long-term buyer here.
02/19/19
MACQ
02/19/19
UPGRADE
Target $24
MACQ
Outperform
Marvell upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Srini Pajjuri upgraded Marvell to Outperform with a price target of $24, saying the estimates on the stock have likely bottomed after its recent pre-announcement. The analyst also finds its discounted valuation at 12-times forward earnings estimates as attractive, with the storage market positioned to recover in the second half of 2019 and added benefits coming from the "strong 5G tailwinds in 2020". Pajjuri adds that Marvell should emerge as a "key beneficiary from the geopolitical issues surrounding Huawei".
STAY Extended Stay America
$18.39

0.4 (2.22%)

03/20/19
JEFF
03/20/19
NO CHANGE
Target $24
JEFF
Buy
Extended Stay America continues to review value strategies, says Jefferies
Jefferies analyst David Katz says that in in light of recent commentary and circumstances, he believes Extended Stay America continues to review value strategies. The highest value-maximizing path could be for the company to split its paired share, sell its C-Corp assets to a strategic acquirer and leave a real estate investment trust entity, Katz tells investors in a research note, citing his calculations. In total, his analysis suggests Extended Stay's combined value ranges between $20 and $33 per share, with $27 per share as the base case or 48% upside from the previous close. The analyst keeps a Buy rating on Extended Stay America with a $24 price target.
03/04/19
GSCO
03/04/19
UPGRADE
GSCO
Buy
Extended Stay America upgraded to Buy from Neutral at Goldman Sachs
03/04/19
GSCO
03/04/19
UPGRADE
Target $21
GSCO
Buy
Goldman Sachs upgrades Extended Stay America on strategic alternatives focus
As previously reported, Goldman Sachs analyst Stephen Grambling upgraded Extended Stay America to Buy from Neutral following the company's Q4 earnings report, noting that he has raised his estimates based on the modest beat and a greater number of company-owned hotels coming online. Additionally, management's renewed focus on strategic alternatives positively skews the risk/reward balance, added Grambling, who has a $21 price target on the stock. Within his calculation of his $21 target, Grambling factors an M&A value of $26 based on comparable transactions and his sum-of-the-parts analysis, he noted.
03/04/19
03/04/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Foot Locker (FL) upgraded to Buy from Hold at Pivotal Research with analyst Mitch Kummetz saying the company on Friday reported much better than expected Q4 results, and its fiscal 2019 same-store-sales and earnings growth outlook was also well above consensus. 2. Hasbro (HAS) upgraded to Market Perform from Underperform at BMO Capital with analyst Gerrick Johnson saying the stock's multiple will expand as "major theatrical events" approach later in the year. 3. Hertz (HTZ) upgraded to Buy from Neutral at Northcoast. 4. Extended Stay America (STAY) upgraded to Buy from Neutral at Goldman Sachs with analyst Stephen Grambling citing the company's Q4 earnings report. 5. Kraft Heinz (KHC) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Dara Mohsenian saying he believes FY19 estimates now look achievable following their recent correction. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
IONS Ionis Pharmaceuticals
$80.53

0.25 (0.31%)

02/28/19
PIPR
02/28/19
NO CHANGE
Target $60
PIPR
Neutral
Ionis Pharmaceuticals price target raised to $60 from $50 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren raised his price target for Ionis Pharmaceuticals to $60 citing a good first quarter for Tegsedi. While early, the $2.2M in sales reported for Tegsedi in the first partial quarter was a surprise to many, compares well to the $0.5M reported in the first Onpattro quarter, and caused the shares to be up significantly yesterday, Van Buren tells investors in a research note. The analyst, however, keeps a Neutral rating on Ionis due to valuation.
12/17/18
NEED
12/17/18
NO CHANGE
Target $82
NEED
Buy
Needham names Ionis a top 2019 pick, boosts target to $82
Needham analyst Chad Messer raised his price target for Ionis Pharmaceuticals to $82 from $67 and named the stock a top pick for 2019. Unlike most other biotech companies, Ionis has been executing on a "perennial innovative pipeline while generating sustainable and growing profits," Messer tells investors in a research note. The company has already produced one blockbuster drug with Spinraza and is in the midst of launching a second potential blockbuster Tegsedim, says the analyst. Further, he points out that four additional programs of the company will reach pivotal trials in 2019. Messer keeps a Buy rating on Ionis Pharmaceuticals.
02/28/19
BMOC
02/28/19
NO CHANGE
Target $82
BMOC
Outperform
Ionis Pharmaceuticals price target raised to $82 from $70 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Ionis Pharmaceuticals to $82 and kept his Outperform rating after its better than expected Q4 results. The analyst is also raising his FY19 and FY20 EPS targets by 28c and 13c to $1.59 and $2.19 respectively on expectations of lower R&D expense projections, adding that more "upside could come from Tegsedi quarterly beats, potential Waylivra refiling, and visibility into an accelerated path for Huntington's".
03/01/19
PIPR
03/01/19
NO CHANGE
Target $63
PIPR
Overweight
Ionis positive CHMP opinion for Waylivra a surprise, says Piper Jaffray
Given the prior Waylivra Complete Response Letter issued by the FDA, the positive Committee for Medicinal Products for Human Use opinion announced this morning was a surprise to many, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The analyst anticipates a European Medicines Agency approval in the coming months and models $150M in European Waylivra sales by the late 2020s "with minimal increase in long-term operating spending." As a result, the analyst boosted his price target for Ionis Pharmaceuticals to $63 from $60 while keeping a Neutral rating on the shares.
PPC Pilgrim's Pride
$21.32

0.71 (3.44%)

07/30/18
JEFF
07/30/18
NO CHANGE
Target $77
JEFF
Underperform
Chicken prices have trended below expectations, says Jefferies
Jefferies analyst Akshay Jagdale says that chicken prices have trended below expectations owing to a further weakening of demand since his last chicken industry update. The analyst attributes the demand weakness to an increase in availability of competing proteins and to a lesser extent lower exports amid trade war concerns. He expects "demand to remain weak and supply growth to pick up." As such, Jagdale lowered his estimates for Sanderson Farms (SAFM), Pilgrim's Pride (PPC) and Tyson Foods (TSN). The analyst keeps an Underperform rating on Sanderson with a $77 price target, Buy rating on Tyson with an $85 price target, and Holding rating on Pilgrim's with a reduced price target of $19.
03/04/19
SPHN
03/04/19
INITIATION
Target $26
SPHN
Overweight
Pilgrim's Pride initiated with an Overweight at Stephens
Stephens analyst Ben Bienvenu started Pilgrim's Pride with an Overweight rating and $26 price target, telling investors that he likes its scale in all of its major geographies and efforts to grow its mix of prepared food and value-added chicken offerings.
08/03/18
SPHN
08/03/18
NO CHANGE
Target $26
SPHN
Overweight
Chicken down cycle already priced into Pilgrim's Pride shares, says Stephens
Stephens analyst Farha Aslam believes Pilgrim's Pride shares are already pricing in the lack of visibility regarding the poultry cycle with the stock's valuation at a five year trough despite the fact that she thinks Pilgrim's Pride "is a better company today than 5 years ago." The analyst, who points to improved U.S. assets, a better product mix and operations in Mexico and the addition of Moy Park in Europe to support her improvement view, keeps an Overweight rating and $26 price target on Pilgrim's Pride.
08/03/18
BMOC
08/03/18
NO CHANGE
Target $20
BMOC
Market Perform
Pilgrim's Pride price target lowered to $20 from $28 at BMO Capital
BMO Capital analyst Kenneth Zaslow lowered his price target on Pilgrim's Pride to $20 and kept his Market Perform rating after its Q2 earnings miss attributed to soft chicken prices and lower profits in Mexico. The analyst states that the company is faced with demand pressure rather than supply issues amid "plentiful competing protein supplies" and limited promotions in food and retail. Zaslow expects Pilgrim's Pride performance to remain constrained by soft chicken prices.
SNBR Sleep Number
$47.83

1.07 (2.29%)

01/28/19
LEHM
01/28/19
INITIATION
Target $36
LEHM
Equal Weight
Sleep Number initiated with an Equal Weight at Barclays
Barclays analyst Matthew McClintock started Sleep Number with an Equal Weight rating and $36 price target. The company does not have the same easy comparisons as Tempur Sealy (TPX) and is further along in gaining the benefit of its direct-to-consumer expansion, McClintock tells investors in a research note.
02/14/19
PIPR
02/14/19
NO CHANGE
Target $43
PIPR
Neutral
Sleep Number price target raised to $43 from $36 at Piper Jaffray
Piper Jaffray analyst Peter Keith raised his price target for Sleep Number to $43 following the "generally positive" Q4 earnings report and "inline-to-slightly disappointing" 2019 guidance. The analyst says that while expected 2019 earnings growth of ~30% at the midpoint is compelling, he remains on the sidelines as valuation "is not overly compelling" given that earnings will likely revert back to mid-teens growth by 2020. Keith keeps a Neutral rating on Sleep Number.
02/14/19
RHCO
02/14/19
NO CHANGE
Target $35
RHCO
Hold
Sleep Number price target raised to $35 from $32 at SunTrust
SunTrust analyst Keith Hughes raised his price target on Sleep Number to $35 after its Q4 earnings beat and "good sales", but notes that given the strong orders in September-October, he expected more. The analyst also keeps his Hold rating on the shares, stating that the high end of the management's "exceptionally wide guidance range of $2.25-$2.75" would be tough to reach and require an "exceptional year" given the "very choppy environment for high-end consumer goods".
09/19/18
WEDB
09/19/18
NO CHANGE
Target $65
WEDB
Outperform
Antidumping petition could lead to relief for mattress cos, says Wedbush
A consortium of U.S. mattress manufacturers yesterday filed an antidumping duty petition with the U.S. Department of Commerce and the U.S. ITC against foam and innerspring mattresses imported from China. In a research note to investors, Wedbush analyst Seth Basham says antidumping duties over 200% could "tip the scales" back in favor of U.S. producers of low-end U.S. mattresses like Tempur Sealy's (TPX) Sealy, but says the impact for Sleep Number (SNBR) is "more limited" with no exposure to the low-mattress segment, and that Purple (PRPL) could benefit "modestly." The analyst believes that more important for Tempur Sealy is the fate of Mattress Firm (MFRM), the largest U.S. mattress retailer, which he continues to expect to file near-term for bankruptcy.
XPER Xperi
$24.29

0.38 (1.59%)

02/21/19
CHLM
02/21/19
NO CHANGE
Target $32
CHLM
Buy
Xperi price target raised to $32 from $28 at Craig-Hallum
Craig-Hallum analyst Richard Shannon reiterated a buy rating on Xperi and raised his price target to $32 from $28 after the company reported Q4 results in line with its preannouncement and guided 2019 EPS higher than consensus. Shannon tells investors in a research note that Xperi's guidance provides certainty and stability after a tough couple of years and provides a basis for investors to think about potential growth and earnings leverage, which should help valuation.
12/10/18
BNCH
12/10/18
NO CHANGE
Target $35
BNCH
Buy
Xperi settlement removes Samsung uncertainty, says Benchmark
After Xperi (XPER) announced a patent license agreement with Samsung (SSNLF) that it said settles all outstanding legal matters between the parties, Benchmark analyst Gary Mobley said he believes the pact "removes nearly all of the uncertainty that has plagued the shares during the past two years." He raised his price target on Xperi shares to $35 from $25 to account for his higher FY19 estimates and keeps an Buy rating on the stock, which he still views as undervalued.
12/11/18
RILY
12/11/18
NO CHANGE
Target $30
RILY
Buy
Xperi price target raised to $30 from $23 at B. Riley FBR
B. Riley FBR analyst Eric Wold raised his price target for Xperi to $30 after the company agreed to a settlement/dismissal of all litigation against Samsung in exchange for new patent license agreement. Along with Broadcom (AVGO) license,the Samsung news helps validate Xperi management's pivot away from outsourced semiconductor and test services providers to manufacturers, Wold tells investors in a research note. He now has increased confidence in the company's upcoming major license renewals and its ability to reduce litigation spend in 2019. The analyst keeps a Buy rating on Xperi.
12/11/18
CHLM
12/11/18
NO CHANGE
Target $28
CHLM
Buy
Xperi price target raised to $28 from $20 at Craig-Hallum
Craig-Hallum analyst Richard Shannon raised his price target for Xperi to $28 from $20 (XPER), while reiterating a Buy rating on the shares. The analyst notes that the the company's Samsung (SSNLF) settlement is a critical event in its history as it shows that its portfolio has substantial ongoing value, and that Xperi is willing to be patient to find a fair settlement.

TODAY'S FREE FLY STORIES

TBIO

Translate Bio

$11.01

0.405 (3.82%)

21:06
09/17/19
09/17
21:06
09/17/19
21:06
Syndicate
Translate Bio 9M share Spot Secondary priced at $10.00 »

Citi, Jefferies and SVB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

SWK

Stanley Black & Decker

$144.45

0.73 (0.51%)

21:05
09/17/19
09/17
21:05
09/17/19
21:05
Downgrade
Stanley Black & Decker rating change  »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

LEN

Lennar

$53.10

-0.23 (-0.43%)

21:02
09/17/19
09/17
21:02
09/17/19
21:02
Downgrade
Lennar rating change  »

Lennar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

WHR

Whirlpool

$152.15

3.4 (2.29%)

21:02
09/17/19
09/17
21:02
09/17/19
21:02
Downgrade
Whirlpool rating change  »

Whirlpool downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TELL

Tellurian

$8.33

-0.1 (-1.19%)

20:44
09/17/19
09/17
20:44
09/17/19
20:44
Initiation
Tellurian initiated  »

Tellurian initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

20:41
09/17/19
09/17
20:41
09/17/19
20:41
Initiation
NextDecade initiated  »

NextDecade initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LINX

Linx S.A.

$7.74

0.22 (2.93%)

20:32
09/17/19
09/17
20:32
09/17/19
20:32
Recommendations
Linx S.A. analyst commentary  »

Linx S.A. offers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Conference/Events
Morgan Stanley steel analyst to hold an analyst/industry conference call »

China Materials Analyst…

GIS

General Mills

$55.03

0.48 (0.88%)

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 01

    Oct

ROAD

Construction Partners

$14.39

-0.42 (-2.84%)

20:10
09/17/19
09/17
20:10
09/17/19
20:10
Syndicate
Construction Partners 5M share Secondary priced at $14.25 »

Construction Partners 5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 18

    Sep

NVST

Envista

$0.00

(0.00%)

19:58
09/17/19
09/17
19:58
09/17/19
19:58
Syndicate
Envista 26.77M share IPO priced at $22.00 »

The deal priced inside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

INVH

Invitation Homes

$28.49

0.31 (1.10%)

19:51
09/17/19
09/17
19:51
09/17/19
19:51
Syndicate
Invitation Homes 44M share Spot Secondary priced at $28.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

, NCMI

National CineMedia

$8.35

0.25 (3.09%)

19:49
09/17/19
09/17
19:49
09/17/19
19:49
Hot Stocks
AMC Entertainment corrects 'inaccurate' statement by National CineMedia »

AMC Entertainment (AMC)…

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

NCMI

National CineMedia

$8.35

0.25 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

BA

Boeing

$384.61

5.74 (1.52%)

19:01
09/17/19
09/17
19:01
09/17/19
19:01
Hot Stocks
House panel invites Boeing CEO to testify on 737 MAX »

Chair of the House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

O

Realty Income

$75.76

1.81 (2.45%)

18:56
09/17/19
09/17
18:56
09/17/19
18:56
Hot Stocks
Realty Income raises monthly cash dividend to 22.7c per share from 22.65c »

Realty Income Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

, CDW

CDW

$113.91

0.94 (0.83%)

18:54
09/17/19
09/17
18:54
09/17/19
18:54
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: NewLink (NLNK) up…

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

CDW

CDW

$113.91

0.94 (0.83%)

TELL

Tellurian

$8.33

-0.1 (-1.19%)

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

FDX

FedEx

$173.53

-0.14 (-0.08%)

XPO

XPO Logistics

$73.83

-0.76 (-1.02%)

CHWY

Chewy

$30.20

-0.2 (-0.66%)

ADBE

Adobe

$284.59

1.54 (0.54%)

IOTS

Adesto Technologies

$10.63

-0.66 (-5.85%)

PTCT

PTC Therapeutics

$43.26

0.27 (0.63%)

TBIO

Translate Bio

$11.01

0.405 (3.82%)

ACAD

Acadia

$42.60

-1.45 (-3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 23

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 23

    Oct

  • 27

    Oct

  • 13

    Nov

  • 18

    Sep

  • 18

    Sep

  • 18

    Sep

YUMA

Yuma Energy

$5.08

-0.05 (-0.97%)

18:51
09/17/19
09/17
18:51
09/17/19
18:51
Hot Stocks
Yuma Energy enters forbearance agreement with lender YE Investment »

Yuma Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$284.59

1.54 (0.54%)

18:45
09/17/19
09/17
18:45
09/17/19
18:45
Hot Stocks
Adobe CEO: We experienced growth across all of our segments »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Oct

  • 27

    Oct

ARAY

Accuray

$3.09

-0.03 (-0.96%)

18:37
09/17/19
09/17
18:37
09/17/19
18:37
Hot Stocks
Data in Lancet Oncology discloses lower toxicity for Accuray Cyberknife patients »

Accuray announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBK

FB Financial

$38.33

-0.36 (-0.93%)

18:29
09/17/19
09/17
18:29
09/17/19
18:29
Hot Stocks
FB Financial acquires FNB Financial »

FB Financial, parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 13

    Nov

GM

General Motors

$38.28

1.07 (2.88%)

18:28
09/17/19
09/17
18:28
09/17/19
18:28
Periodicals
GM stops paying health insurance costs for union workers on strike, Reuters says »

General Motors has moved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOT

Total

$52.85

0.08 (0.15%)

18:25
09/17/19
09/17
18:25
09/17/19
18:25
Periodicals
Total CEO says Saudi oil facility strikes will have consequences, Reuters says »

Total CEO Patrick…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

SMMF

Summit Financial Group

$25.96

-0.29 (-1.10%)

18:02
09/17/19
09/17
18:02
09/17/19
18:02
Hot Stocks
Summit Financial and Cornerstone Financial sign merger agreement »

Summit Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLD

Steel Dynamics

$30.93

-0.89 (-2.80%)

18:01
09/17/19
09/17
18:01
09/17/19
18:01
Earnings
Steel Dynamics sees Q3 EPS 66c-70c, consensus 71c »

Steel Dynamics provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$173.53

-0.14 (-0.08%)

18:00
09/17/19
09/17
18:00
09/17/19
18:00
Hot Stocks
Breaking Hot Stocks news story on FedEx »

FedEx says FY21 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.